OakChart

Evolus Inc

EOLSHealthcare·Drug Manufacturers - Specialty & Generic·USA·Small·NASD·Nov 11 • 3:59 PM ET

7.42+0.61 (8.96%)
2026-11-12 00:30 CET
Market cap
450.74 USD m
Revenue, TTM
325.47 USD m
Net income, TTM
-31.11 USD m
Free cash flow, TTM
-4.91 USD m
EPS diluted, TTM
-0.47
P/E
-
Compare

Price

EOLS against its 20, 50 and 200-day averages
2050200beatmiss
5.006.007.008.009.002.9M5.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26EOLSclose 7.4220-day 7.2550-day 7.70200-day 6.357.4252w high

20.3% under the 52-week high of 9.31 on 4 Sep 2026. 52-week low 3.86 on 30 Mar 2026. Last 15 sessions, 22.1% high to low

Volume 1.36× normal · the line is the 50-bar volume average

Profile

EOLS
52-week range, 65% of the way up
3.869.31

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.

IndexRUT
Employees334
IPOFeb 08, 2018
Beta1.35
ATR, 14d0.40
Rel volume1.36
Short float10.39%
Insider own12.44%
Inst own73.41%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap491.11M
Enterprise Value615.00M
Income-31.11M
Sales325.47M
Book/sh-0.57
Cash/sh0.63
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees334
IPOFeb 08, 2018

Ratios

P/E-
Forward P/E22.48
PEG-
P/S1.51
P/B-
P/C11.78
P/FCF-
EV/EBITDA-
EV/Sales1.89
Quick Ratio0.84
Current Ratio1.42
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.47
EPS next Y0.33
EPS next Q0.06
EPS this Y92.60%
EPS next Y1115.38%
EPS next 5Y-
EPS past 3/5Y15.49% 30.19%
Sales past 3/5Y25.98% 39.36%
EPS Y/Y TTM48.13%
Sales Y/Y TTM13.87%
EPS Q/Q22.09%
Sales Q/Q13.03%
EarningsNov 04 AMC
EPS/Sales Surpr.27.42% 0.54%

Ownership

Insider Own12.44%
Insider Trans-1.26%
Inst Own73.41%
Inst Trans7.28%
ROA-12.38%
ROE-
ROIC-24.98%
Gross Margin64.51%
Oper. Margin-4.99%
Profit Margin-9.56%
SMA202.29%
SMA50-3.60%
SMA20016.94%
Trades-

Technical

Shs Outstand66.14M
Shs Float57.96M
Short Float10.39%
Short Ratio6.35
Short Interest6.02M
52W High9.31 -20.30%
52W Low3.86 92.23%
Volatility6.68% 5.20%
ATR (14)0.40
RSI (14)51.33
Beta1.35
Rel Volume1.36
Avg Volume948.83K
Volume1,287,349

Performance

Perf Week-0.67%
Perf Month-1.20%
Perf Quarter-7.48%
Perf Half Y10.42%
Perf YTD11.58%
Perf Year6.15%
Perf 3Y-7.25%
Perf 5Y2.20%
Perf 10Y-
Recom1.33
Target Price15.40
Prev Close6.81
Price7.42
Change %8.96%

Analyst ratings

latest 10 of 18
DateActionAnalystRating changeTargetImplied
Aug 06, 2025DowngradeNNeedhamBuy → Hold
Apr 17, 2025InitiatedBBTIG ResearchBuy$21+183.0%
Jan 29, 2024UpgradeBBarclaysEqual Weight → Overweight$10 → $16+115.6%
Jun 23, 2022InitiatedNNeedhamBuy$18+142.6%
May 12, 2022UpgradeBBarclaysUnderweight → Equal Weight$8 → $10+34.8%
Jan 20, 2022UpgradeTTruistHold → Buy$11+48.2%
May 06, 2021UpgradeMMizuhoNeutral → Buy$15+102.2%
Apr 08, 2021ReiteratedHH.C. WainwrightBuy$20 → $22+196.5%
Feb 24, 2021DowngradeTTruistBuy → Hold$12+61.7%
Jul 07, 2020DowngradeMMizuhoBuy → Neutral$8 → $3-59.6%

Peers

Mkt cap
TickerCompanyMkt cap
ABBVAbbvie Inc521.41B
INMDInmode Ltd790.08M
BHCBausch Health Companies Inc3.13B
DERMJourney Medical Corp125.31M
ESTAEstablishment Labs Holdings Inc2.11B
COLLCollegium Pharmaceutical Inc770.99M
APYXApyx Medical Corp126.37M
SKINSkinHealth Systems Inc109.07M
AIRSAirsculpt Technologies Inc59.55M
BTMDbiote Corp60.74M

Insider trading

10 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
MOATAZEDI DAVIDSee RemarksSep 02 '26Sale9.04105,108950,019499,592Sep 04 07:04 PM
DAVID MOATAZEDIOfficerSep 02 '26Proposed Sale9.04105,108950,019Sep 02 04:55 PM
Avelar RuiSee RemarksMar 20 '26Sale4.753,11914,815427,423Mar 20 07:19 PM
MOATAZEDI DAVIDSee RemarksMar 20 '26Sale4.7513,66964,929604,700Mar 20 07:19 PM
MOATAZEDI DAVIDSee RemarksMar 16 '26Option Exercise0.0067,4890735,089Mar 18 08:00 PM
MOATAZEDI DAVIDSee RemarksMar 17 '26Sale4.89116,720570,562618,369Mar 18 08:00 PM
Avelar RuiSee RemarksMar 16 '26Option Exercise0.008,8040460,538Mar 18 08:00 PM
Avelar RuiSee RemarksMar 17 '26Sale4.8929,996146,629430,542Mar 18 08:00 PM
MOATAZEDI DAVIDSee RemarksDec 22 '25Sale7.1510,53975,361354,388Dec 29 06:42 PM
Avelar RuiSee RemarksDec 22 '25Sale7.152,26116,168356,821Dec 29 06:42 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 516.35M
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IHEiShares U.S. Pharmaceuticals ETFAUM: 1.72B
IWCiShares Micro-Cap ETFAUM: 1.22B
VHTVanguard Health Care ETFAUM: 21.51B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.045-0.062-0.19078.0077.585
2026Q22026-08-050.007-0.033-0.12284.0881.556
2026Q12026-05-04-0.046-0.113-0.16473.1472.526
2025Q42026-03-030.0440.0450.00290.3089.536
2025Q32025-11-05-0.132-0.163-0.24368.9767.386
2025Q22025-08-05-0.247-0.099-0.26669.3982.047
2025Q12025-05-07-0.149-0.141-0.29768.5272.366
2024Q42025-03-040.0330.008-0.10778.9579.005
2024Q32024-11-06-0.162-0.123-0.30461.0963.176
2024Q22024-07-31-0.040-0.053-0.18166.9164.934
2024Q12024-05-07-0.083-0.152-0.22359.3357.277
2023Q42024-03-07-0.125-0.124-0.20761.0060.198
2023Q32023-11-07-0.165-0.223-0.29750.0044.358
2023Q22023-08-02-0.195-0.253-0.31949.3549.307
2023Q12023-05-09-0.151-0.186-0.26241.7240.578
2022Q42023-03-08-0.137-0.168-0.23443.6543.899

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-2.559-3.089-3.18834.9333.46
2020FY-1.895-1.741-4.83256.5457.10
2021FY-1.021-0.974-0.94199.6799.77
2022FY-0.968-0.920-1.327148.62148.81
2023FY-0.626-0.556-1.084202.09201.28
2024FY-0.251-0.270-0.813266.27266.3
2025FY-0.439-0.451-0.800297.18296.47
2026FY--0.033--334.3
2027FY-0.330--390.69
2028FY-0.662--459.65
2029FY-1.173--537.87
2030FY-1.840--608.83

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0760198.9898.20100.6
2026Q4S2026-11-0561198.9898.20100.6
2026Q4S2026-11-0462099.3198.40100.8
2026Q4S2026-10-2062099.3198.40100.8
2026Q4S2026-10-1364199.3198.40100.8
2026Q4S2026-10-0764199.3198.40100.8
2026Q4S2026-09-1463198.9798.40100.18
2026Q4S2026-08-2474199.4198.40102
2026Q4S2026-08-1763199.2898.40102
2026Q4S2026-08-1363199.2698.40102
2026Q4S2026-08-0673199.0097.44102
2026Q4S2026-07-1971098.5796.70101
2026Q4S2026-07-1773098.5796.70101
2026Q4S2026-07-1073098.5396.70100.71

Estimate history

EPS, annual-0.27-1.921-3.188-4.832-0.941-1.327-1.084-0.813-0.801-0.4733
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.304-0.107-0.297-0.266-0.2430.002-0.164-0.122-0.189
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0034.92556.5499.673148.616202.085266.274297.176325.47
Period201720182019202020212022202320242025TTM
Sales, quarterly61.08578.94768.52269.38768.96790.373.13784.08477.952
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual16.52727.27533.56333.74955.57756.26157.82163.49865.00866.142
Period201720182019202020212022202320242025MRQ
Shares, quarterly63.25163.49864.44964.63964.76665.00865.8466.01466.142
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue325.47297.18266.27202.09148.6299.6756.5434.920.00
Cost of Goods Sold Incl. D&A115.51104.4186.3166.6959.6149.1625.3312.150.01
Gross Profit209.96192.76179.96135.3989.0150.5231.2122.78-0.01
Selling, General and Administrative Excl. Other226.19230.36207.20171.50148.58114.1399.91117.5735.63
Research and Development9.589.589.176.566.742.061.723.976.49
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-16.23-37.60-27.23-36.11-59.58-63.62-68.70-94.79-35.64
Interest Expense16.3719.6918.7313.839.101.4010.507.950.86
Unusual Expense-0.63-4.947.1813.135.75-18.2484.374.1610.50
Net Income Before Taxes-30.34-50.96-49.76-61.51-74.32-46.77-162.94-105.06-46.80
Income Taxes0.770.680.660.180.100.040.08-15.030.07
Consolidated Net Income-31.11-51.64-50.42-61.69-74.41-46.81-163.01-90.03-46.87
Net Income From Continuing Operations-31.11-51.64-50.42-61.69-74.41-46.81-163.01-90.03-46.87
Net Income-31.11-51.64-50.42-61.69-74.41-46.81-163.01-90.03-46.87
EPS (Recurring)-0.48-0.85-0.73-0.92-1.26-1.20-3.08-3.09-1.62
EPS (Basic, Before Extraordinaries)-0.47-0.80-0.81-1.08-1.33-0.94-4.83-3.19-1.92
EPS (Diluted)-0.47-0.80-0.81-1.08-1.33-0.94-4.83-3.19-1.92
EBITDA-5.28-28.86-21.21-30.24-55.08-57.30-61.02-89.78-35.63
Non-Operating Income (Expense)1.631.393.391.560.110.000.641.840.20
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense16.9916.3517.5313.008.566.997.736.955.51
Price To Sales Ratio1.621.442.572.972.833.252.009.84-
Gross Margin64.5164.8667.5967.0059.8950.6855.2165.22-
Operating Margin-4.99-12.65-10.23-17.87-40.09-63.82-121.50-271.40-
Net Margin-9.56-17.38-18.94-30.52-50.07-46.96-288.31-257.79-
Shares Outstanding66.1465.0163.5057.8256.2655.5833.7533.5627.27
Market Capitalization450.74450.74699.07601.80422.41361.81113.40406.78324.57

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue77.9584.0873.1490.3068.9769.3968.5278.95
Cost of Goods Sold Incl. D&A28.8428.4325.7832.4524.2725.0022.6929.98
Gross Profit49.1155.6547.3657.8444.7044.3945.8348.97
Selling, General and Administrative Excl. Other54.8958.9454.2258.1454.8658.5158.8552.67
Research and Development1.971.892.243.482.051.842.212.43
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-5.78-3.29-6.86-0.29-10.16-14.12-13.02-3.70
Interest Expense4.254.173.983.984.097.214.424.57
Unusual Expense2.651.25-0.01-4.511.34-3.912.151.56
Net Income Before Taxes-12.23-8.21-10.420.52-15.57-17.09-18.82-6.35
Income Taxes0.28-0.150.260.390.170.050.070.44
Consolidated Net Income-12.52-8.05-10.670.13-15.74-17.14-18.89-6.79
Net Income From Continuing Operations-12.52-8.05-10.670.13-15.74-17.14-18.89-6.79
Net Income-12.52-8.05-10.670.13-15.74-17.14-18.89-6.79
EPS (Recurring)-0.16-0.11-0.16-0.05-0.23-0.31-0.27-0.09
EPS (Basic, Before Extraordinaries)-0.19-0.12-0.160.00-0.24-0.27-0.30-0.11
EPS (Diluted)-0.19-0.12-0.160.00-0.24-0.27-0.30-0.11
EBITDA-2.80-0.60-4.172.30-7.88-12.08-11.20-2.09
Non-Operating Income (Expense)0.440.510.410.270.020.330.770.54
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.434.454.044.074.073.554.684.82
Price To Sales Ratio1.621.450.891.461.392.142.782.63
Gross Margin63.0066.1964.7564.0664.8163.9766.8962.03
Operating Margin-7.42-3.92-9.38-0.32-14.74-20.36-19.00-4.69
Net Margin-16.06-9.58-14.590.14-22.82-24.70-27.57-8.60
Shares Outstanding66.1466.0165.8465.0164.7764.6464.4563.50
Market Capitalization450.74457.03267.40431.05397.17593.82764.95699.07

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments53.8386.9562.8453.92146.26107.56129.8093.160.00
Short Term Receivables54.7047.6830.5322.4514.669.6810.660.0072.64
Inventories26.9612.1611.0018.851.763.356.410.000.00
Other Current Assets7.434.558.065.5816.127.025.331.180.18
Total Current Assets142.92151.34112.42100.80178.80127.61152.2094.3472.82
Net Property, Plant & Equipment12.5010.417.854.564.094.714.970.000.00
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets69.2569.9668.3269.8171.8376.5080.8577.2877.28
Other Assets1.200.860.412.812.760.242.430.222.12
Total Assets225.87232.57189.00177.98257.48209.07240.44171.84152.23
Short Term Debt Incl. Current Port. of LT Debt2.531.721.381.321.2694.661.200.00211.33
Accounts Payable23.369.244.278.946.099.625.800.000.00
Other Current Liabilities49.4252.0142.6436.2550.3175.9717.445.281.42
Total Current Liabilities75.3162.9648.2946.5157.66180.2524.445.28212.75
Long Term Debt152.47128.26125.1773.102.2643.6595.3516.900.00
Provision for Risks Charges0.000.000.000.005.0020.000.000.000.00
Deferred Tax Liabilities0.030.010.030.020.040.03-15.0514.99
Other Liabilities21.1735.8236.2039.85110.6538.1041.2050.230.04
Total Liabilities248.97227.05209.69159.48175.61282.03160.9987.46227.78
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-23.115.52-20.6918.5081.88-72.9679.4684.38-75.54
Total Shareholders Equity-23.115.52-20.6918.5081.88-72.9679.4684.38-75.54
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-23.115.52-20.6918.5081.88-72.9679.4684.38-75.54
Total Liabilities & Stockholders Equity225.87232.57189.00177.98257.48209.07240.44171.84152.23
Book Value Per Share-0.360.09-0.360.331.47-2.162.373.09-4.57
Tangible Book Value Per Share-1.42-1.01-1.54-0.910.18-4.43-0.040.26-9.25
Full-Time Employees3343322732151671192357021
Price to Book Ratio-11.91118.56-31.0414.444.42-1.555.143.853.42
Return on Assets-22.53-23.92-33.62-34.18-20.07-72.53-43.68-28.92-3.90
Return on Equity----148.27-1,049.79-5,016.56-109.90-1,060.22-
Return on Invested Capital-39.92-37.69-59.04-81.23-55.64--51.51-46.27-
Quick Ratio1.542.212.101.763.070.695.9717.880.34
Current Ratio1.902.402.332.173.100.716.2317.880.34

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-31.11-51.64-50.42-61.69-74.41-46.81-163.01-90.03-46.87
Depreciation10.958.746.025.874.506.317.685.000.01
Other Funds (Non Cash)26.3423.0933.0327.7019.2718.6461.8327.5118.33
Funds from Operations5.29-19.79-11.39-28.11-50.66-21.84-93.47-72.58-28.46
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-7.94-22.48-6.60-5.89-34.25-11.5435.60-20.812.79
Cash from Operating Activities-2.65-42.27-18.00-34.01-84.91-33.39-57.87-93.38-25.67
Capital Expenditures-6.17-8.45-4.82-1.63-2.94-0.97-3.14-4.57-0.01
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments0.000.000.000.000.005.0015.33-18.870.00
Purchase of Investments0.000.000.000.000.000.00-74.67-113.870.00
Sale Or Maturity of Investments0.000.000.000.000.005.0090.0095.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-6.17-8.45-4.82-1.63-2.944.0312.19-23.43-0.01
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.541.164.630.220.54103.780.0075.57122.95
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.541.164.630.220.54103.780.0075.57122.95
Proceedsfrom Stock Options1.161.16-0.250.000.00103.120.0075.57122.95
Issuance or Reduction of Debt, Net9.34-0.010.0049.950.00-27.6339.4870.66-3.87
Change in Long Term Debt9.34-0.010.0049.950.00-7.63-0.5270.660.00
Issuance of Long Term Debt9.350.000.0049.950.0068.690.0071.700.00
Reduction of Long Term Debt-0.02-0.010.000.000.00-76.32-0.52-1.040.00
Net Financing Active Other Cash Flow-2.4416.1942.78-5.54-4.18-3.10-1.13-12.68-0.24
Other Financing Activities Uses-2.44-8.81-8.43-5.54-4.18-3.10-1.13-12.68-0.24
Cash from Financing Activities7.4317.3447.4144.64-4.1573.0538.35133.55118.84
Exchange Rate Effect-0.440.25-0.48-0.09-0.34----
Net Change in Cash-1.82-33.1324.118.92-92.3343.69-7.3316.7393.16
Free Cash Flow-4.91-45.71-19.47-34.48-86.53-33.78-58.69-93.73-25.68
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.02-0.020.01-0.020.010.03-15.050.07

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments41.7045.1749.7953.8343.5261.74
Short Term Receivables60.2862.3852.2254.7050.4447.71
Inventories82.8040.9024.8026.9632.8726.46
Other Current Assets16.9519.0912.127.438.069.07
Total Current Assets201.74167.54138.92142.92134.89144.97
Net Property, Plant & Equipment11.9411.4812.1212.5012.6011.48
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets67.9466.9067.9569.2569.9370.56
Other Assets2.212.101.651.201.581.80
Total Assets283.82248.02220.65225.87219.00228.80
Short Term Debt Incl. Current Port. of LT Debt3.212.572.552.532.482.39
Accounts Payable86.1944.4819.5323.3622.9623.31
Other Current Liabilities52.9851.6845.9449.4241.2838.05
Total Current Liabilities142.3898.7368.0275.3166.7163.75
Long Term Debt162.37162.23162.35152.47152.42152.51
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.010.010.020.03-0.02
Other Liabilities16.8817.9519.0321.1728.6331.17
Total Liabilities321.64278.93249.43248.97247.76247.46
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-37.81-30.90-28.78-23.11-28.76-18.65
Total Shareholders Equity-37.81-30.90-28.78-23.11-28.76-18.65
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-37.81-30.90-28.78-23.11-28.76-18.65
Total Liabilities & Stockholders Equity283.82248.02220.65225.87219.00228.80
Book Value Per Share-0.57-0.47-0.44-0.36-0.44-0.29
Tangible Book Value Per Share-1.60-1.48-1.47-1.42-1.52-1.38
Full-Time Employees---334-394
Price to Book Ratio-11.91-15.88-11.56-14.98-21.28-89.88
Return on Assets-12.38-14.40-20.01-22.53-26.11-26.80
Return on Equity------18,729.61
Return on Invested Capital-10.05-6.13-7.990.10-12.73-12.81
Quick Ratio0.841.281.681.541.531.86
Current Ratio1.421.702.041.902.022.27

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-12.52-8.05-10.670.13-15.74-17.14
Depreciation2.982.692.692.592.282.05
Other Funds (Non Cash)8.607.966.013.777.831.92
Funds from Operations-1.262.02-1.986.51-5.65-13.15
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.67-5.61-7.986.32-9.02-11.64
Cash from Operating Activities-1.93-3.59-9.9512.83-14.67-24.79
Capital Expenditures-1.81-0.50-1.69-2.17-2.16-2.27
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-1.81-0.50-1.69-2.17-2.16-2.27
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.140.310.000.080.020.32
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.140.310.000.080.020.32
Proceedsfrom Stock Options0.000.000.001.160.000.00
Issuance or Reduction of Debt, Net-0.04-0.6110.00-0.00-0.00-0.01
Change in Long Term Debt-0.04-0.6110.00-0.00-0.00-0.01
Issuance of Long Term Debt-0.04-0.6110.000.000.000.00
Reduction of Long Term Debt-0.01-0.00-0.00-0.00-0.00-0.01
Net Financing Active Other Cash Flow0.00-0.07-2.380.00-1.7920.35
Other Financing Activities Uses0.00-0.07-2.380.00-1.79-4.65
Cash from Financing Activities0.10-0.367.620.08-1.7720.66
Exchange Rate Effect0.18-0.17-0.01-0.430.380.24
Net Change in Cash-3.47-4.62-4.0310.30-18.21-6.16
Free Cash Flow-2.25-3.64-10.3711.35-15.62-25.48

Revenue breakdown

Evolysse2025: 22.63M
Jeuveau2024: 264.31M 2025: 272.32M
Service2024: 1.97M 2025: 2.22M
Non-US2024: 13.12M
United States2024: 253.16M 2025: 297.18M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.39%6.0M58.0M892.65K
2026-10-1511.08%6.4M57.8M892.19K
2026-09-309.73%5.6M57.8M876.10K
2026-09-159.56%5.5M57.8M915.72K
2026-08-319.28%5.4M57.8M896.36K
2026-08-1410.11%5.9M57.9M845.29K
2026-07-319.62%5.6M57.9M826.01K
2026-07-1510.63%5.9M55.5M849.37K
2026-06-3010.84%6.0M55.5M829.21K
2026-06-1510.61%5.9M55.5M861.06K
2026-05-2910.91%6.1M55.5M1.13M
2026-05-1511.12%6.2M55.5M1.10M
2026-04-3013.75%6.7M48.4M1.06M
2026-04-1513.28%6.6M49.8M1.15M
2026-03-3113.08%6.5M49.8M1.32M
2026-03-1315.29%7.6M49.8M1.29M
2026-02-2715.67%7.8M49.8M1.04M
2026-02-1316.39%7.8M47.6M1.16M
2026-01-3014.88%7.4M49.7M1.43M
2026-01-1513.83%6.9M49.7M1.35M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.502.506.500.0015.5390.000.000.966-0.0910.001
call5.000.404.901.8510.37516.000.000.830-0.1380.003
call7.500.001.050.252.36036.0010.000.589-0.0800.004
call10.000.000.050.051.2755,02520.000.081-0.0130.002
call12.500.004.900.001.9430.000.000.058-0.0150.001
call15.000.004.900.002.4450.000.000.049-0.0160.001
put2.500.004.900.0018.7230.000.00-0.034-0.0910.001
put5.000.004.900.108.3164.000.00-0.170-0.1370.003
put7.500.001.900.754.09548.000.00-0.411-0.0790.004
put10.001.004.600.006.0930.000.00-0.919-0.0110.002
put12.503.507.500.007.9640.000.00-0.942-0.0130.001
put15.006.0010.000.008.6920.000.00-0.951-0.0140.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-09SCHEDULE 13G/ASEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-08-31SCHEDULE 13GSEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-08-048-KCurrent report2026-08-03SEC
2026-07-088-KCurrent report2026-07-07SEC
2026-06-12EFFECTEffectiveness filing by commission orderSEC
2026-06-128-KCurrent report2026-06-11SEC
2026-06-10CORRESPSEC
2026-06-10UPLOADUpload SubmissionSEC
2026-06-05S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-05-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-048-KCurrent report2026-05-04SEC
2026-04-29DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-29DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-11SEC
2026-04-29ARSAnnual report to security holders. 2025-12-31SEC
2026-03-26SCHEDULE 13G/ASEC
2026-03-204Statement of changes in beneficial ownership of securities2026-03-20SEC
2026-03-204Statement of changes in beneficial ownership of securities2026-03-20SEC
2026-03-184Statement of changes in beneficial ownership of securities2026-03-16SEC
2026-03-184Statement of changes in beneficial ownership of securities2026-03-16SEC
2026-03-138-KCurrent report2026-03-13SEC
2026-03-0310-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-038-KCurrent report2026-03-03SEC
2026-03-03S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-02-194Statement of changes in beneficial ownership of securities2026-02-17SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0900950.02K1
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-0300796.94K4
2026-020000
2026-010000
2025-120091.53K2
2025-110000

Institutional holders

Manager% owned
Nantahala Capital Management, LLC17.01%
BlackRock, Inc.7.35%
BRAIDWELL LP4.79%
Frazier Life Sciences Management, L.P.3.99%
PERCEPTIVE ADVISORS LLC3.73%
VANGUARD CAPITAL MANAGEMENT LLC3.59%
MILLENNIUM MANAGEMENT LLC2.71%
STATE STREET CORP2.58%
Stonepine Capital Management, LLC2.41%
GEODE CAPITAL MANAGEMENT, LLC2.39%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.35%
iShares Russell 2000 ETF2.34%
VANGUARD EXTENDED MARKET INDEX FUND1.17%
Fidelity Small Cap Index Fund0.98%
iShares Russell 2000 Growth ETF0.85%
VANGUARD RUSSELL 2000 INDEX FUND0.52%
Fidelity Extended Market Index Fund0.50%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF0.49%
Schwab U.S. Small-Cap ETF0.48%
iShares Micro-Cap ETF0.30%

OakChart. EOLS. Cached 15 minutes.